{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"The MTD was determined following a standard 3+3 design is as follows: Escalation at 0/3 DLTs, dose-reduction if \\>1/3 DLT, and expansion to 6 if 1/3 DLTs. DLT is defined as the severe toxicity event that leads to the termination of the treatment as defined in section 5.5. The highest dose level where \\<2/6 DLTs are observed will be declared MTD","groups":[{"description":"Patients who received at least 80% of PO triapine (either at 100mg or 150mg) and 80% of chemoradiation.","id":"OG000","title":"All Participants"}],"paramType":"NUMBER","populationDescription":"All treated patients evaluable for DLTs","reportingStatus":"POSTED","timeFrame":"Up to 5 weeks","title":"Maximum Tolerated Dose (MTD)","type":"PRIMARY","unitOfMeasure":"mg"}